Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

461 - Synthesis of folic acid-chitosan bioconjugate system for cancer cell targeting: reaction parameter optimization and characterization


19 Dec 2015


Poster presentation 1


Akhilesh Singh


Annals of Oncology (2015) 26 (suppl_9): 153-155. 10.1093/annonc/mdv534


A.V. Singh

Author affiliations

  • Materials Engineering, Indian Institute of Science, 560012 - Bangalore/IN


Abstract 461


Folic acid (FA) based conjugate systems are frequently used in anticancer drug delivery because of its increased potential for internalization by receptor mediated endocytosis into the cancer cells. The conjugation reaction between conjugating polymer and FA depends on many reaction parameters that affect the degree of conjugation. In this study, an approach to synthesize FA-chitosan (CS) conjugate system was undertaken.


FA-chitosan (CS) conjugate system based on carbodiimide chemistry was developed by conjugating the free carboxyl group of folic acid moiety and primary amine group of CS. Two parameters were optimized: (i) reaction duration [4 to 48 h] and (ii) concentration of N-hydroxysuccinimide [0.25-1.00 g] to know their effect on percentage of conjugation. The conjugate formed was confirmed by FT-IR, and percentage conjugation of FA was analyzed by UV spectroscopy. The highly conjugated FA-CS system was further characterized by XRD, DSC and TGA. The morphology and bio-compatibility parameters were also studied by SEM and MTT assay, respectively.


We found that conjugation was efficient when the reaction duration and NHS concentration were ≥24 h and 0.75 g, respectively. The bio-conjugate system formed was more amorphous as confirmed by XRD, DSC and TGA analysis. The conjugated material did not exhibit any cytotoxicity in HeLa cells.


The results showed a potential to be used this material in anti-cancer drug delivery application.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings